Fourth Amendment to Loan Agreement, dated May 22, 2023, among Smart for Life, Inc., Bonne Sante Natural Manufacturing, Inc., Doctors Scientific Organica, LLC and Diamond Creek Capital, LLC

Exhibit 10.30

FOURTH AMENDMENT TO LOAN AGREEMENT

THIS FOURTH AMENDMENT TO THE LOAN AGREEMENT (this “Fourth Amendment”), dated and effective as of May 22, 2023, amends the Loan Agreement dated as of July 1, 2021 and amended from time to time by and between Smart For Life, Inc., a Delaware corporation (“SFL” or the “Company”), and Diamond Creek Capital, LLC, a Delaware limited liability company (“Lender”) (as amended, the “Loan Agreement”). Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in the Loan Agreement (as defined below).

WHEREAS, the Lender, and the Company (formerly, Bonne Santé Group, Inc.), Doctors Scientific Organica, LLC, a Florida limited liability company (“DSO”), Bonne Santé Natural Manufacturing, Inc., a Florida corporation (“BSNM”), Nexus Offers, Inc., a Florida corporation (“Nexus”), GSP Nutrition, Inc., a Florida corporation (“GSP”) and Ceautamed Worldwide, LLC, a Florida limited liability company (“Ceautamed’) and together with the Company, DSO, BSNM, Nexus, and GSP, the “Borrower”), are parties to (i) the Loan Agreement dated July 1, 2021 and amended from time to time, and (ii) Security Agreement dated July 1, 2021 (the “Security Agreement” and together with the promissory note and any other agreements relating thereto, the “Loan Agreements”).

RECITALS

I. WHEREAS, Borrower and Lender desire to amend certain terms of the Loan Agreement;

II. WHEREAS, the Borrower currently has an outstanding principal balance of $975,000 in Loans under the Loan Agreement identified above as of May 15, 2023; accrued and unpaid interest on such Loans of $6.093.75 through and including May 15, 2023; and an outstanding Monitoring Fee in the amount of $1,000.00 as of May 15, 2023.

NOW, THEREFORE, in consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties, intending to be legally bound, hereby agree as follows:

1. Definitions. Section 1.01 of the Loan Agreement is hereby amended to delete and replace the following definition:

“Maturity Date” means the earlier of (a) July 1, 2023, and (b) such earlier date on which the Loan is due and payable (whether at stated maturity, by acceleration or otherwise) in accordance with the terms of this Agreement.”

2. Waiver and Amendments. Lender shall agree to waive the financial covenants specified in Section 2.04 (d) EBITDA Deficit and Section 5.02 (n) Funded Debt/EBITDA Ratio of the Loan Agreement through the Maturity Date, as amended by this Fourth Amendment to the Loan Agreement. Furthermore, Borrower and Lender agree to amend the subject covenants in tandem with the execution of the Fourth Amendment. In the event that the Loan remains outstanding beyond the Maturity Date, Section 2.04 (d) EBITDA Deficit of the Loan Agreement shall be reinstated as follows: “While any principal under this Agreement is outstanding, the aggregate Funded Debt shall not exceed three (3) times the annualized three (3) month EBITDA of Borrower, as measured on a quarterly basis 30 days after each calendar quarter (commencing on June 30, 2023), based on the annualized 3 month period ending on the last day of such calendar quarter. In the event any such measurement reveals an aggregate outstanding Funded Debt in excess of the limit set forth above (“EBITDA Deficit”), the Borrower shall make a prepayment against the outstanding principal amount under this Agreement equal to the EBITDA Deficit, within 30 days of the EBITDA Deficit measurement. For the avoidance of doubt, EBITDA shall be calculated on an annualized run rate basis during the duration of this Fourth Amendment.”

Section 5.02 (n) Funded Debt/EBITDA Ratio of the Loan Agreement shall be reinstated as follows: “Borrower shall not permit the aggregate Funded Debt during the annualized three (3) month period to exceed three (3) times the annualized trailing three (3) month EBITDA of Borrower, as measured on a quarterly basis on and after June 30, 2023. For the avoidance of doubt, EBITDA shall be calculated on an annualized run rate basis.”

3. Extension, Waiver and Amendment Fee. Lender shall receive an aggregate Extension, Waiver and Amendment Fee in the amount of $7,500.00 for agreeing to waive the subject financial covenants through the Maturity Date, and agree to the aforementioned amendments. Lender and Borrower agree that the Waiver Fee will be paid concurrent with the execution of the Fourth Amendment.

4. Reaffirmation. The Loan Agreement, as amended hereby, shall be and remain in full force and effect in accordance with its respective terms and hereby is ratified and confirmed in all respects. Borrower ratifies and reaffirms the continuing effectiveness of all agreements entered into in connection with the Agreement. Borrower confirms that after giving effect to this Amendment, an Event of Default has not occurred and is not continuing.

5. Loan Agreement. Except as expressly amended and modified by this Fourth Amendment (and any prior amendments), the Loan Agreement shall remain in full force and effect.

6. Counterparts. This Fourth Amendment may be executed in any number of counterparts, any of which may be executed and transmitted by facsimile or electronic mail transmission, and each of which will be deemed to be an original of this Amendment, and all of which, when taken together, shall be deemed to constitute one and the same agreement.

[signature page follows]

IN WITNESS WHEREOF, the parties hereto have caused this Waiver to be executed and delivered as of the date first above written.

Bonne Santé Natural Manufacturing, Inc.,

a Florida corporation

Doctors Scientific Organica, LLC,

a Florida limited liability company

3